Quebec’s decision not to cover Wegovy, a prescription medication used for chronic weight management, continues to spark debate among patients, healthcare providers and policymakers. Despite growing evidence of its effectiveness in helping individuals with obesity achieve meaningful weight loss, the provincial government has maintained its stance against public reimbursement, citing cost concerns as the primary barrier. The medication, which contains semaglutide as its active ingredient, carries a monthly price tag estimated between CAD 300 and 500 out-of-pocket for patients, placing it financially out of reach for many who might benefit most.
This position reflects broader tensions within Canada’s healthcare system regarding the coverage of newer, high-cost obesity treatments. While Wegovy received approval from Health Canada in 2021 for utilize alongside diet and exercise in adults with obesity or overweight with at least one weight-related comorbidity, provincial formularies have been slow to add it to publicly funded drug lists. Quebec’s refusal aligns with similar decisions in other provinces, though some jurisdictions like Alberta and Saskatchewan have implemented limited coverage under specific criteria. The ongoing discussion underscores the challenge of balancing clinical innovation with fiscal sustainability in public drug plans.
The drug works by mimicking a hormone called glucagon-like peptide-1 (GLP-1), which regulates appetite and food intake. Clinical trials have shown that patients taking Wegovy can lose an average of 15% of their body weight over 68 weeks when combined with lifestyle changes, significantly outperforming placebo groups. For individuals struggling with obesity-related conditions such as type 2 diabetes, hypertension, or sleep apnea, this level of weight reduction can translate into meaningful improvements in health outcomes and quality of life. However, access remains uneven across the country.
In Quebec, the Institut national d’excellence en santé et en services sociaux (INESSS) evaluates medications for potential inclusion in the public drug plan. In its most recent review, INESSS concluded that while Wegovy demonstrates clinical benefit, the budgetary impact outweighs the perceived value at current pricing. The institute has called for price negotiations with the manufacturer, Novo Nordisk, before reconsidering coverage. This cost-effectiveness threshold is a standard part of Canada’s drug review process, designed to ensure responsible use of public funds.
Patient advocacy groups have voiced frustration over the decision, arguing that obesity should be treated as a chronic disease deserving of the same level of support as other long-term conditions. “Denying access to effective treatments perpetuates stigma and ignores the biological complexity of weight regulation,” said a representative from the Canadian Obesity Network, now known as Obesity Canada, in a 2023 statement. They emphasize that untreated obesity contributes significantly to healthcare costs through complications like heart disease, kidney failure, and joint degeneration.
Healthcare professionals note that off-label use or reliance on private insurance creates a two-tier system where only those with financial means can access the medication. Some clinicians report prescribing lower-dose formulations of semaglutide approved for diabetes (such as Ozempic) as an alternative, though this practice raises concerns about supply shortages for diabetic patients who depend on those versions. Health Canada has previously issued warnings about using diabetes medications for weight loss without proper medical supervision due to risks of hypoglycemia and gastrointestinal side effects.
Internationally, several countries have taken different approaches. The United Kingdom’s National Health Service (NHS) began offering Wegovy through specialized weight management services in 2023 under strict eligibility criteria. In the United States, coverage varies widely by state and insurer, though Medicare Part D now includes some anti-obesity medications under recent legislative changes. These contrasting policies highlight the lack of consensus on how to integrate pharmacological interventions into broader obesity care strategies.
Researchers continue to study the long-term effects of semaglutide-based therapies, including cardiovascular outcomes and durability of weight loss after discontinuation. A major trial published in 2023 found that participants who stopped taking Wegovy regained a significant portion of lost weight within a year, underscoring the necessitate for ongoing treatment in many cases. This finding reinforces the argument that obesity management often requires sustained intervention rather than short-term fixes.
For residents of Quebec seeking information about coverage decisions or appeal processes, the Régie de l’assurance maladie du Québec (RAMQ) provides updates on its website regarding changes to the public prescription drug insurance plan. Individuals can also consult with their healthcare providers about alternative strategies, including behavioral therapy, nutritional counseling, or other approved medications that may be covered under existing criteria.
As the conversation evolves, stakeholders agree that any solution must address both access and equity. Until pricing agreements are reached or provincial policies shift, many Quebecers will continue to face tricky choices between their health and their household budgets when considering treatment options for obesity.
Stay informed about developments in Quebec’s drug coverage policies by checking official announcements from INESSS and RAMQ. Share your perspective on this important public health issue in the comments below, and help spread awareness by sharing this article with others who may be affected.